Abstract: Provided herein is a method of extending the lifespan of an organism comprising administering to the organism an effective amount of a ferroptosis inhibitor. Also provided are compositions for extending lifespan comprising ferroptosis inhibitors.

Abstract: The present invention relates in general to the field of compositions and methods for using N-acetylcysteine amide (NACA) or (2R,2R?)-3,3?-disulfanediyl bis(2-acetamidopropanamide) (diNACA) for treating or alleviating a disorder or condition associated with ferroptosis, which can cause or contribute to diseases, disorders and conditions including aging associated with declining cognition, cognitive impairment, declining physical function, physical decline, elevated inflammation, endothelial dysfunction, insulin resistance, central obesity, loss of muscle mass (sarcopenia), neurological diseases and disorders, including neurodegeneration, stroke, including ischemic stroke and post-hemorrhagic stroke damage, and neurotrauma, including traumatic brain injury, Alzheimers disease, Huntington's disease, Niemann-Pick disease, Parkinson's disease, motor neuron disease, Amyotrophic Lateral Sclerosis, Sedaghatian-type spondylo-metaphyseal dysplasia, cancer, including breast cancer, kidney injuries including ischemia-re

Abstract: In one embodiment, the present application discloses a method of reducing senescence in a mammal by reducing the concentration of non-ferritin iron within the mammal, comprising the administration of a therapeutically effective amount of an iron chelator or an antioxidant, or a pharmaceutically acceptable salt thereof.

Abstract: This invention relates to methods and compositions for the treatment or alleviation of Alzheimer's disease and of other conditions related to abnormal protein aggregation. In particular, the invention relates to methods and compositions for the immunotherapy of Alzheimer's disease, Parkinson's disease, and cataract. In one aspect the invention provides a method of prophylaxis, treatment or alleviation of a condition characterized by pathological aggregation and accumulation of a specific protein associated with an immunizing-effective dose of one or more tyrosine cross-linked compounds, and optionally also comprising copper ions complexed to the compound. Alternatively passive immunization against a tyrosine cross-linked compound may be used. Prophylactic or therapeutic compositions and diagnostic methods are also disclosed and claimed.

Abstract: The present invention relates generally to therapeutic agents, formulations comprising them and their use in the treatment, amelioration and/or prophylaxis of glioma brain tumors and related conditions. The therapeutic agent comprises two fused 6-membered rings with at least a nitrogen at position 1 and a hydroxyl at position 8.

Abstract: The present invention relates generally to the field of treatment and prophylaxis of retinal degenerative diseases. More particularly, the present invention contemplates a method for preventing, reducing the risk of development of, or otherwise treating or ameliorating the symptoms of, age-related macular degeneration (AMD) or related retinal conditions in mammals and in particular humans. The present invention further provides therapeutic compositions enabling dose-dependent or dose-specific administration of agents useful in the treatment and prophylaxis of age-related macular degeneration or related retinal degenerative conditions.

Abstract: The present invention relates generally to the field of treatment and prophylaxis of retinal degenerative diseases. More particularly, the present invention contemplates a method for preventing, reducing the risk of development of, or otherwise treating or ameliorating the symptoms of, age-related macular degeneration (AMD) or related retinal conditions in mammals and in particular humans. The present invention further provides therapeutic compositions enabling dose-dependent or dose-specific administration of agents useful in the treatment and prophylaxis of age-related macular degeneration or related retinal degenerative conditions.

Abstract: The present invention relates generally to therapeutic agents, formulations comprising them and their use in the treatment, amelioration and/or prophylaxis of glioma brain tumours and related conditions. The therapeutic agent comprises two fused 6-membered rings with at least a nitrogen at position 1 and a hydroxyl at position 8.

Abstract: This invention relates to methods and compositions for the treatment or alleviation of Alzheimer's disease and of other conditions related to abnormal protein aggregation. In particular, the invention relates to methods and compositions for the immunotherapy of Alzheimer's disease, Parkinson's disease, and cataract. In one aspect the invention provides a method of prophylaxis, treatment or alleviation of a condition characterized by pathological aggregation and accumulation of a specific protein associated with an immunizing-effective dose of one or more tyrosine cross-linked compounds, and optionally also comprising copper ions complexed to the compound. Alternatively passive immunization against a tyrosine cross-linked compound may be used. Prophylactic or therapeutic compositions and diagnostic methods are also disclosed and claimed.

Abstract: This invention relates to methods and compositions for the treatment or alleviation of Alzheimer's disease and of other conditions related to abnormal protein aggregation. In particular, the invention relates to methods and compositions for the immunotherapy of Alzheimer's disease, Parkinson's disease, and cataract. In one aspect the invention provides a method of prophylaxis, treatment or alleviation of a condition characterized by pathological aggregation and accumulation of a specific protein associated with an immunizing-effective dose of one or more tyrosine cross-linked compounds, and optionally also comprising copper ions complexed to the compound. Alternatively passive immunization against a tyrosine cross-linked compound may be used. Prophylactic or therapeutic compositions and diagnostic methods are also disclosed and claimed.

Abstract: The invention provides a method of diagnosing, prognosing, staging, and/or monitoring a mammalian amyloidogenic disorder or a predisposition thereto by detecting a protein or polypeptide aggregate in the cortical and/or supranuclear regions of an ocular lens of the mammal.

Abstract: A method for psychological testing of a subject is performed by (A) presenting a test by means of a testing means having output means (e.g. a computer monitor) and input means (e.g. a keyboard); and, (B) instructing the subject by displaying a simulation (as shown in the figure) of the test by means of the output means so that the subject can learn how to perform the test from the simulation. The test is therefore independent of the subject's language skills, or of verbal instructions provided by a supervisor.

Abstract: The invention relates to the identification of clioquinol as a pharmaceutically therapeutic agent for treatment of Alzheimer's disease and related pathological conditions.

Abstract: A method for psychological testing of a subject is performed by (A) presenting a test by means of a testing means having output means (e.g. a computer monitor) and input means (e.g. a keyboard); and, (B) instructing the subject by displaying a simulation (as shown in the figure) of the test by means of said output means so that the subject can learn how to perform the test from the simulation. The test is therefore independent of the subject's language skills, or of verbal instructions provided by a supervisor.

Abstract: A system and method of diagnosing the onset and monitoring the progression of cognitive impairment may incorporate administering one or more psychological tests and instructing a subject regarding rules for responding to the one or more tests without providing cultural cues such as may be introduced in language-based instruction techniques. Proper test responses may be simulated during an instruction phase preceding the testing phase. An apparatus, system, and method of testing cognitive function may be implemented in a computerized system.

Abstract: The invention relates to methods for identifying candidate pharmacological agents to be used in the treatment and/or prevention of Alzheimer's disease and/or related pathological conditions.

Abstract: Described are methods for the identification of agents useful in the treatment or prevention of cataracts. Also described are methods for the identification of agents that may inadvertently promote or accelerate the formation of cataracts, and methods of treating or preventing injuries to or diseases of the ocular lens, retina and/or macular. More specifically, the invention describes methods for the identification of pharmacological agents useful in treating cataracts by inhibiting the cross-linking of eye lens proteins.

Abstract: The present invention relates generally to a method of modulating glutathione metabolism in the central nervous system of mammals and to agents for use therein. More particularly, the present invention relates to a method of up-regulating glutathione metabolism in the central nervous system by up-regulating levels of glutathione precursor molecules. The method of the present invention is particularly useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by aberrant, unwanted or otherwise inappropriate central nervous system oxidation homeostasis including, but not limited to, schizophrenia.

Abstract: This invention relates to methods and compositions for the treatment or alleviation of Alzheimer's disease and of other conditions related to abnormal protein aggregation. In particular, the invention relates to methods and compositions for the immunotherapy of Alzheimer's disease, Parkinson's disease, and cataract. In one aspect the invention provides a method of prophylaxis, treatment or alleviation of a condition characterized by pathological aggregation and accumulation of a specific protein associated with an immunizing-effective dose of one or more tyrosine cross-linked compounds, and optionally also comprising copper ions complexed to the compound. Alternatively passive immunization against a tyrosine cross-linked compound may be used. Prophylactic or therapeutic compositions and diagnostic methods are also disclosed and claimed.

Abstract: A system and method of diagnosing the onset and monitoring the progression of cognitive impairment may incorporate administering one or more psychological tests and instructing a subject regarding rules for responding to the one or more tests without providing cultural cues such as may be introduced in language-based instruction techniques. Proper test responses may be simulated during an instruction phase preceding the testing phase. An apparatus, system, and method of testing cognitive function may be implemented in a computerized system.